

DFW

PTO/SB/21 (09-04)

Approved for use through 07/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE


Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

TRANSMITTAL FORM <i>(to be used for all correspondence after initial filing)</i>	Application Number	10/827,121	
	Filing Date	April 16, 2004	
	First Named Inventor	John D. Baxter	
	Group Art Unit	1631	
	Examiner Name	Carolyn L. Smith	
Total Number of Pages in This Submission	11	Attorney Docket Number	407J-981114US

ENCLOSURES (check all that apply)		
<input type="checkbox"/> Fee Transmittal Form	<input type="checkbox"/> Executed Assignment	<input type="checkbox"/> After Allowance Communication to Group
<input type="checkbox"/> Fee Attached	<input type="checkbox"/> Recordation Coversheet	<input type="checkbox"/> Appeal Communication to Board of Appeals and Interferences
<input type="checkbox"/> Amendment / Response	<input type="checkbox"/> Licensing-related Papers	<input type="checkbox"/> Appeal Communication to Group <i>(Appeal Notice, Brief, Reply Brief)</i>
<input type="checkbox"/> After Final	<input type="checkbox"/> Petition Routing Slip (PTO/SB/69) and Accompanying Petition	<input type="checkbox"/> Proprietary Information
<input type="checkbox"/> Affidavits/declaration(s)	<input type="checkbox"/> Petition to Convert to a Provisional Application	<input type="checkbox"/> Status Letter
<input type="checkbox"/> Extension of Time Request	<input type="checkbox"/> Power of Attorney, Revocation Change of Correspondence Address	<input checked="" type="checkbox"/> Additional Enclosure(s) <i>(please identify below):</i>
<input type="checkbox"/> Express Abandonment Request	<input type="checkbox"/> Terminal Disclaimer	receipt acknowledgment postcard
<input checked="" type="checkbox"/> Information Disclosure Statement	<input type="checkbox"/> Small Entity Statement	
<input type="checkbox"/> Certified Copy of Priority Document(s)	<input type="checkbox"/> Request for Refund	
<input type="checkbox"/> Response to Missing Parts/ Incomplete Application	Authorization to Charge Deposit Account Please charge Deposit Account No. 50-0893 for any additional fees associated with this paper or during the pendency of this application, including any extensions of time for consideration of the documents enclosed.	
<input type="checkbox"/> Response to Missing Parts under 37 CFR 1.52 or 1.53	Remarks	

SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT	
Firm or Individual name	Gary Baker, Reg. No. 41,595, Quine Intellectual Property Law Group P.C.
Signature	
Date	January 7, 2005

CERTIFICATE OF MAILING			
I hereby certify that this correspondence is being facsimile transmitted to the USPTO via fax no. 703-306-5995 or deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on the date shown below.			
Typed or printed name	Deborah Berwick		
Signature		Date	January 7, 2005



I hereby certify that this correspondence is being deposited with the United States Postal Service first class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450 Alexandria, VA 22313-1450, on January 7, 2005

QUINE INTELLECTUAL PROPERTY LAW GROUP, P.C.

By Deborah Berwick
Deborah Berwick

Attorney Docket No. 407J-981114US
Client Ref. No. 96-026-5

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:

John D. Baxter, et al.

Application No.: 10/827,121

Filed: April 16, 2004

For: NUCLEAR RECEPTOR LIGANDS
AND LIGAND BINDING DOMAINS

Examiner: Carolyn L. Smith

Art Unit: 1631

INFORMATION DISCLOSURE
STATEMENT UNDER 37 CFR § 1.97 and
§ 1.98

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:


The references cited on the attached PTO-1449 form are being called to the attention of the Examiner to make of record references cited in parent application USSN 08/980,115 (now U.S. Patent 6,266,622) filed November 26, 1997. An additional 1449 form citing an additional reference is also enclosed. A copy of the newly cited reference is enclosed. Pursuant to 37 CFR § 1.98(d), copies of references cited in parent application USSN 08/980,115 (now U.S. Patent 6,266,622) filed November 26, 1997 are not provided. However the applicants will gladly provide fresh copies of any references requested by the Examiner.

It is respectfully requested that the cited information on the attached 1449 form(s) be expressly considered during the prosecution of this application, and that references be made of record therein and appear among the "references cited" on any patent to issue therefrom.

As provided for by 37 CFR 1.97(g) and (h), no inference should be made that the information and references cited are prior art merely because they are in this statement and no representation is being made that a search has been conducted or that this statement encompasses all the possible relevant information.

Applicant believes that no fee is required for submission of this statement, since it is being submitted prior to the first Office Action. However, if a fee is required, the Commissioner is authorized to deduct such fee from the undersigned's Deposit Account No. 50-0893. Please deduct any additional fees from, or credit any overpayment to, the above-noted Deposit Account.

Respectfully submitted,

A handwritten signature in black ink, appearing to read "Gary Baker", is written over a horizontal line.

Gary Baker
Reg. No. 41,595

QUINE INTELLECTUAL PROPERTY LAW GROUP, P.C.
P.O. BOX 458
Alameda, CA 94501
(510) 337-7871
Fax (510) 337-7877

GB:db

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A-B/PTO

INFORMATION DISCLOSURE
STATEMENT BY APPLICANT

JAN 1 1 1995 (as many sheets as necessary)

Complete if Known

Application Number	10/827,121
Filing Date	April 16, 2004
First Named Inventor	John D. Baxter
Group Art Unit	1631
Examiner Name	Carolyn L. Smith
Attorney Docket Number	407J-981114US
Date Submitted	January 7, 2005

U.S. PATENT DOCUMENTS

Examiner Initials	Cite No.	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, lines, Where Relevant Passages or Relevant Figures Appear
		Number	Kind Code (if known)			
	1	4,741,897		Andrews et al.	05-03-1988	
	2	4,766,121		Ellis et al.	08-23-1988	
	3	4,826,876		Ellis et al.	05-02-1989	
	4	4,910,305		Ellis et al.	03-20-1990	
	5	5,061,798		Emmett et al.	10-29-1991	
	6	5,116,828		Miura et al.	05-26-1992	
	7	5,171,671		Evans et al.	12-15-1992	
	8	5,284,999		Chin et al.	02-08-1994	
	9	5,312,732		Evans	05-17-1994	
	10	5,322,933		Davies et al.	06-21-1994	
	11	5,403,925		Ozato	04-04-1995	
	12	5,438,126		DeGroot et al.	08-01-1995	
	13	5,463,564		Agrafiotic et al.	10-31-1995	
	14	5,466,861		Dawson et al.	11-14-1995	

FOREIGN PATENT DOCUMENTS

Examiner Initials	Cite No.	Foreign Patent Document			Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T
		Office	Number	Kind Code (if known)				
	15	EP	355,628			08-11-1989		
	16	WO	97/21993		Regents of the University of California	06-19-1997		
	17	WO	98/07435		Regents of the University of California	02-26-1998		
	18	WO	98/57919		Regents of the University of California	12-23-1998		

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A-B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(use as many sheets as necessary)</i>	Complete if Known	
	Application Number	10/827,121
	Filing Date	April 16, 2004
	First Named Inventor	John D. Baxter
	Group Art Unit	1631
	Examiner Name	Carolyn L. Smith
	Attorney Docket Number	407J-981114US
	Date Submitted	January 7, 2005

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS			
Examiner Initials	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T
	19	ANDREA ET AL. (1979) "A model for Thyroid Hormone-Receptor Interactions." <i>J. Med. Chem.</i> 22: 221-232	
	20	APRILETTI ET AL (1988) "Large Scale Purification of the Nuclear Thyroid Hormone Receptor From Rat Liver and Sequence-specific Binding of the Receptor to DNA." <i>J. Biol. Chem.</i> 263:9409-9417.	
	21	APRILETTI ET AL. (1995) "Expression of the rat $\alpha 1$ Thyroid Hormone Receptor Ligand Binding Domain in Escherichia coli and the Use of a Ligand-Induced" <i>Protein Expression and Purification</i> 6:363-370	
	22	AU-FLIEGNER ET AL. (1993) "The Conserved Ninth C-Terminal Heptad in Thyroid Hormone and Retinoic Acid receptors Mediates Diverse Responses by Affecting Heterodimer but Not Homodimer Formation." <i>Mol Cell Biol.</i> 13:5725-5737.	
	23	BANIAHMAD ET AL. (1995) "The $\tau 4$ Activation Domain of the Thyroid Hormone Receptor is Required for Release of a Putative Corepressor(s) Necessary for Transcriptional Silencing." <i>Mol. Cell Biol</i> 15:76-86.	
	24	BARETTINO ET AL. (1994) "Characterization of the Ligand-dependent Transactivation Domain of Thyroid Hormone receptor." <i>EMBO Journal</i> 13:3039-3049.	
	25	BARKER ET AL. (1960) "Thyroxine Antagonism by Partially Iodinated Thyronines and Analogues." <i>Ann N.Y. Acad. Sci.</i> 86:545-562.	
	26	BECK-PECCOZ ET AL. (1994) "Nomenclature of Thyroid Hormone Receptor β -Gene Mutations in Resistance to Thyroid Hormone. . ." July 10-11 1993 Cambridge, United Kingdom. <i>J. Clin.Endocrinol Metab.</i> 78:990-993.	
	27	BHAT ET AL. (1995) "Interaction of Thyroid Hormone Nuclear Receptor with Antibody: Characterization of the Thyroid Hormone Binding Site." <i>Biochem. Biophys. Res Commun.</i> 210:464-471.	
	28	BLAKE AND OATLEY (1977) "Protein-DNA and Protein-Hormone Interactions in prealbumin : a Model of the Thyroid Hormone Nuclear Receptor?" <i>Nature</i> 268:115-120.	
	29	BLAKE ET AL. (1978) "Structure of Prealbumin: Secondary, Tertiary and Quarternary Interactions Determined by Fourier Refinement at 1.8 Å" <i>J. Mol. Biol.</i> 121:339-356.	
	30	BOLGER ET AL. (1980) Molecular Interactions Between Thyroid Hormone Analogs and the Rat Liver Nuclear Receptor." <i>Journal of Biological Chemistry</i> 255(21): 10271-10278.	
	31	BOURGUET ET AL. (1995) "Crystal Structures of the Ligands-Binding Domain of the Human Receptor RXR- α ." <i>Nature</i> 375:377-382.	
	32	BRENT (1994) "The Molecular Basis of Thyroid Hormone Action." <i>New England Journal of Medicine</i> 331:847-853.	
	33	BRUNGER ET AL. (1987) "Crystallographic R Factor Refinement by Molecular Dynamics." <i>Science</i> 235:458-460.	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A-B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(use as many sheets as necessary)</i>	Complete if Known	
	Application Number	10/827,121
	Filing Date	April 16, 2004
	First Named Inventor	John D. Baxter
	Group Art Unit	1631
	Examiner Name	Carolyn L. Smith
	Attorney Docket Number	407J-981114US
	Date Submitted	January 7, 2005

34	CASANOVA ET AL. (1994) "Functional Evidence for Ligand-Dependent Dissociation of Thyroid Hormone and Retinoic Acid Receptors from an Inhibitory Cellular Factor." <i>Mol Cell. Biol.</i> 14:5756-5765.	
35	CAVAILLES ET AL. (1995) "Nuclear Factor RIP140 Modulates Transcriptional Activation by the Estrogen Receptor." <i>EMBO Journal</i> 14:3741-3751.	
36	CHANG ET AL. (1997) "A Thyroid Hormone Receptor Coactivator Negatively Regulated by the Retinoblastoma Protein." <i>Proceedings of the National Academy of Sciences USA</i> 94(17): 9040-9045.	
37	CHIELLINI ET AL. (1998) "A High-Affinity Subtype-Selective Agonist for the Thyroid Hormone Receptor." <i>Chemistry and Biology</i> 5(6): 299-306.	
38	COLLABORATIVE COMPUTATIONAL PROJECT, N. 4. (1994) "The CCP4 Suite: Programs for Protein Crystallography." <i>Acta Crystallogr D</i> 50:760-763.	
39	COLLINGWOOD ET AL. (1994) Spectrum of Transcriptional, Dimerization, and Dominant Negative Properties of Twenty Different Mutant Thyroid Hormone β -Receptors in Thyroid Hormone Resistance Syndrome." <i>Mol Endocrinol</i> 8:1262-1277.	
40	COWAN ET AL. (1991) "Improved Methods for Building Protein Models in Electron Density Maps and the Location of Errors in These Models." <i>Acta Crystallogr A</i> 47:110-119.	
41	COWTAN (1994) <i>Journ CCP4 and ESF-EACBM Newsletter of Protein Crystallography</i> 31:34-38.	
42	CROWE ET AL. (1994) "6xHis-Ni-NTA Chromatography as a Superior Technique in Recombinant Protein Expression/Purification." <i>Methods in Molecular Biology</i> 31:371-387.	
43	DAMM AND EVANS (1993) "Identification of a Domain Required for Oncogenic Activity and Transcription suppression by v-erbA and Thyroid-Hormone Receptor α ." <i>Proceedings of the National Academy of Sciences USA</i> 90:10668-10672.	
44	DANIELIAN ET AL. (1992) "Identification of a Conserved Region Required for Hormone Dependent Transcriptional Activation by Steroid Hormone Receptors." <i>EMBO Journal</i> 11:1025-1033.	
45	DIETRICH ET AL. (1977) "Thyroxine Analogues. 23. Quantitative Structure-Activity Correlation Studies of in Vivo and in Vitro Thyromimetic Activities." <i>J. Med. Chem.</i> 20:863-880.	
46	DURAND ET AL. (1994) "Activation Function 2 (AF-2) of Retinoic Acid Receptor and 9-cis Retinoic Acid Receptors: Presence of a Conserved Autonomous Constitutive Activated Domain" <i>EMBO Journal</i> 13:5370-5382.	
47	EVANS (1988) "The Steroid and Thyroid Hormone Receptor Superfamily." <i>Science</i> 240:889-895.	
48	FAWELL ET AL. (1990) "Characterization and Colocalization of Steroid Binding and Dimerization Activities in the Mouse Estrogen Receptor." <i>Cell</i> 60:953-962.	
49	FORMAN AND SAMUELS (1990) "Interactions Among a Subfamily of Nuclear Hormone Receptors: The Regulatory Zipper Model." <i>Mol. Endocrinol</i> 4:1293-1301.	
50	GEWIRTH AND SIGLER (1995) "The Basis for Half-Site Specificity Explored Through a Non-Cognate Steroid Receptor-DNA Complex." <i>Nature Structural Biology</i> 2:386-394.	
51	GLASS (1994) "Differential Recognition of Target Genes by nuclear Receptor Monomers, Dimers, and Heterodimers," <i>Enocr. Rev.</i> 15:391-407.	
Examiner Signature		Date Considered

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A-B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(use as many sheets as necessary)</i>	Complete if Known	
	Application Number	10/827,121
	Filing Date	April 16, 2004
	First Named Inventor	John D. Baxter
	Group Art Unit	1631
	Examiner Name	Carolyn L. Smith
	Attorney Docket Number	407J-981114US
	Date Submitted	January 7, 2005

52	HAJDUK ET AL. (1997) "Discovering High Affinity Ligands for Proteins." <i>Science</i> 278:497-499.	
53	HAYASHI ET AL. (1994) "Mutations of CpG Dinucleotides Located in the Triiodothyronine (ts)-Binding Domain of the Thyroid Hormone Receptor. . ." <i>J.Clin. Invest.</i> 94:607-615.	
54	HEERY ET AL. (1997) "A Signature Motif in Transcriptional Co-activators Mediated Binding to Nuclear Receptors." <i>Nature</i> 387:733-736.	
55	HOLLENBERG ET AL. (1995) "Ligand-Independent and -Dependent Functions of Thyroid Hormone Receptors Isoforms Depend Upon Their Distinct Amino Termini." <i>J. Biol. Chem.</i> 270(24):14274-14280.	
56	HORWITZ (1992) "The Molecular Biology of RU486." <i>Endocrine</i> 13:146-163	
57	JACKSON (1997) "Contributions of Protein Structure-based drug Design to Cancer Chemotherapy," <i>Seminats on Oncology</i> 24(2): L164-172.	
58	JANCARIK AND KIM (1991) "Sparse Matrix Sampling: A screening Method for Crystallization of Proteins." <i>J. Appl. Crystallogr</i> 24:409-411.	
59	JANKNECHT (1991) "Rapid and Efficient Purification of Native Histidine-Tagged Protein Expressed by Recombinant Vaccinia Virus." <i>Proceeding sof the National Academy of Sciences USA</i> 88:8972-8976.	
60	JONES ET AL. (1991) "Improved Methods for Building Protein Models in Electron Density Maps and the Location of Error in These Models." <i>ACTA Cryst.</i> 47:110-119.	
61	JONES ET AL. (1996) "Structure-Based Design of Lipophilic Quinazoline Inhibitors of Thymidylate Synthase." <i>J. Med. Chem.</i> 39(4): 904-917.	
62	JORGENSEN (1978) "Thyroid Hormones and Analogs IN 6 Hormonal Proteins and Peptides." <i>Thyroid Hormones</i> 150-151.	
63	JORGENSEN (1978) "Thyroid Hormones and Analogs." <i>Hormonal Peptides and Proteins</i> 107-204 (Academic Press, New York,)	
64	JORGENSEN ET AL. (1976) "The Nature of the thyroid Hormone Receptor." <i>Thyroid Research</i> 378:303-306.	
65	KABSCH (1993) "Automatic Processing of Rotation Diffraction Data From Crystals of Initially Unknown Symmetry and Cell Constants." <i>Appl. Crystallogr</i> 26:795-800.	
66	KABSCH AND SANDER (1983) "Dictionary of Protein Secondary Structure: Pattern Recognition of Hydrogen-Bonded and Geometrical features." <i>Biopolymers</i> 22:2577-2637.	
67	KAKIZAWA ET AL. (1997) "Ligand-dependent Heterodimerization of Thyroid Hormone Receptor and Retinoid X Receptor." <i>J. Biol. Chem.</i> 272(38): 23799-23804.	
68	KEDIEL ET AL. (1994) "Different Agonist and Antagonist Induced Conformational Changes in Retinoic Acid Receptors Analyzed by Protease Mapping." <i>Mol Cell Biol</i> 14:287-298.	
69	LASKOWSKI ET AL. (1993) "Procheck" a Program to Check the Stereochemical Quality of Protein Structures." <i>J. Appl. Crystallogr</i> 26:283-291.	
70	LATHAM ET AL. (1981) "Development of Support Matrices for Affinity Chromatography of Thyroid Hormone Receptors." <i>J. Biol Chem.</i> 256:12088-12093.	
71	LAUDET (1992) "Evolution of the Nuclear Receptor Gene Superfamily." <i>EMBO Journal</i> 11:1003-1013.	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A-B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(use as many sheets as necessary)</i>	Complete if Known	
	Application Number	10/827,121
	Filing Date	April 16, 2004
	First Named Inventor	John D. Baxter
	Group Art Unit	1631
	Examiner Name	Carolyn L. Smith
	Attorney Docket Number	407J-981114US
	Date Submitted	January 7, 2005

72	LEDOUARIN ET AL. (1995) "The N-Terminal Part of TIF1, a Putative Mediator of the Ligand-Dependent Activation Function . . ." <i>EMBO Journal</i> 14:2020-2033.	
73	LEE (1995) "Interaction of Thyroid-Hormone Receptor with a Conserved Transcriptional Mediator." <i>Nature</i> 374:91-94.	
74	LEE ET AL. (1995) "Two Classes of Proteins Dependent on Either the Presence or Absence of thyroid Hormone for Interaction with the Thyroid Hormone Receptor." <i>Molec. Endocrinol</i> 9:243-254.	
75	LEESON ET AL. (1989) "Selective Thyromimetics." <i>J. Med. Chem</i> 32:320-336.	
76	LEESON ET AL. (1989) "Thyroid Hormone Analogues." <i>J. Med. Chem.</i> 31:37-54.	
77	LEITMAN ET AL. (1991) "Identification of a Tumor Necrosis Factor-Responsive Element in the Tumor Necrosis Factor α Gene." <i>J. Biol Chem.</i> 266:9343.	
78	LENG ET AL. (1993) "Ligand-Dependent Conformational Changes in Thyroid Hormone and Retinoic Acid Receptors..." <i>J Steroid. Biochem. Molec. Biol.</i> 46:643-661.	
79	LENG ET AL. (1995) "Mouse Retinoid X Receptor Contains a Separable Ligand-Binding and Transactivation Domain in its E Region." <i>Mol. And Cellular Biol.</i> 15:255-263.	
80	LEWIS AND WALLBANK (1987) "Formation of Quinol Ethers Using (Diacetoxyiodo) Benzene." <i>Synthesis</i> 1103.	
81	LIN ET AL. (1991) "An Essential Role of Domain D in the Hormone-Binding Activity of Human β 1 Thyroid Hormone Nuclear Receptor." <i>Mol. Endocrinol</i> 5:485-492.	
82	LIN ET AL. (1997) "A conformatinal Switch in Nuclear Hormone Receptors is Involved in Coupling Hormone Binding to Corepressor Release." <i>Mol. Cell. Biol</i> 17(1): 6131-6138	
83	LLEYWEGT ET AL. (1994) "OOPS-a-dasy." <i>ESF/CCP4 Newsletter</i> pp. 20-24.	
84	LUISI ET AL. (1991) "Crystallographic Analysis of the Interaction of the Glucocorticoid Receptor with DNA." <i>Nature</i> 352:497-505.	
85	MCGRATH ET AL. (1989) "Rapid Preparation of Proteins for Crystallization Tials." <i>Biotechniques</i> 7:246-247.	
86	MCGRATH ET AL. (1994) "Preliminary Crystallagraphic Studies of the Ligand-Binding Domain of the Thyroid Hormine Receptor Complexed With Triiodothyronine." <i>J. Mol. Biol.</i> 237:236-239.	
87	MCREE ET AL. (1993) <i>Practical Protein Crystallography</i> Academic Press, N.Y. Chapters 1-3.	
88	MEIER ET AL. (1992) "Variable Transcriptional Activity and Ligand Binding of Mutant β 1 3. 5. 3'-Triiodothyronine Receptors . . ." <i>Mol Endocrinol</i> 6:248-258.	
89	MONACO ET AL. (1995) "Structure of a Comple of Two Plasma Proteins: Transthyretin and Retinol-Binding Protein." <i>Science</i> 268:1039-1041.	
90	MURSHUDOV ET A. (1996) "Application of Maximun Likelihood Methods for Macromolecular Refinements." <i>Refinement of Protein Structures</i> pp. 1-12.	
91	NAVAZA (1994) "AmoRe: an Automated Package for Molecular Replacement." <i>Acta Crystallographica Section A-Funamentals for crystallography</i> 50:157-163.	
92	NICHOLLS ET AL. (1991) "Protein Folding and Association: Insites From the Interfacial and Thermodynamic Properties of Hydrocarbons." <i>Proteins</i> 11:281-296.	
Examiner Signature		Date Considered

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A-B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(use as many sheets as necessary)</i>	Complete if Known	
	Application Number	10/827,121
	Filing Date	April 16, 2004
	First Named Inventor	John D. Baxter
	Group Art Unit	1631
	Examiner Name	Carolyn L. Smith
	Attorney Docket Number	407J-981114US
	Date Submitted	January 7, 2005

93	O'DONNELL ET AL. (1991) "Thyroid Hormone Receptor Mutations that Interfere with Transcriptional Activation Also Interfere with Receptors." <i>Mol Endocrinol</i> 5:94-99.	
94	ONATE ET AL. (1995) "Sequence and characterization of a Coactivator for the Steroid Hormone Receptor Superfamily." <i>Science</i> 270:1354-1357.	
95	OTWINOSKI (1991) "Maximum Likelihood Refinement of Heavy Atom Parameters." <i>Proceedings of the CCP4 Study Weekend: Data Collection and Processing</i> 80-86.	
96	OTWINOSKI (1993) "Ossillation Data Reduction Program." <i>Proceedings of the CCP4 Study Weekend: Data Collection and Processing</i> 56-62.	
97	RASTINEJAD ET AL. (1995) "Structural Determinants of Nuclear Receptor Assembly on DNA Direct Repeats." <i>Nature</i> 375:203-211.	
98	RAYNAUD ET AL. (1986) "The Design and Use of Sex-Steroid Antagonist." <i>J. Steroid Biochem</i> 25:811-833.	
99	REFETTOFF ET AL. (1993) "The Syndromes of Resistance to Thyroid Hormone." <i>Endocr. Rev.</i> 14:248-399.	
100	RIBEIRO ET AL. (1992) "Thyroid Hormone Alters in Vitro DNA Binding of Monomers and dimers of Thyroid Hormone Receptors." <i>Mol. Endocrinol.</i> 6:1142-1152..	
101	RIBEIRO ET AL. (1995) "The Molecular Biology of Thyroid Hormone Action." <i>Ann. N.Y. Acad. Sci.</i> 758:366-389.	
102	RIBEIRO ET AL. (1995) "The Nuclear Hormone Receptor Gene Superfamily." <i>Annu. Rev. Med.</i> 46:443-453.	
103	RIBEIRO ET AL. (1998) "Mechanism of Thyroid Hormone Action: Insights from X-Ray Crystallographic and Functional Studies." <i>Recent Progress in Hormone Research</i> 53:351-394.	
104	ROBSSEAU ET AL. (1972) "Glucocorticoid Receptors: Relations Between Steroid Binding and Biological Effects." <i>J. Mo. Biol.</i> 67:99-115.	
105	SAATCIOGLU ET AL. (1993) "A Conserved C-Terminal Sequence that is Deleted in v-ErbA is Essential for the Biological Activities of c-ErbA (The Thyroid Hormone Receptor)." <i>Mol. Cell. Biol.</i> 13:3675-3685.	
106	SCHWABE ET AL. (1993) "The Crystal Structure of the Estrogen Receptor DNA-Binding Domain Bound to DNA: How Receptors Discriminate Between Their Response Elements." <i>Cell</i> 75:567-578.	
107	SEIELSTAD ET AL. (1995) "Molecular Characterization by Mass Spectrometry of the Human Estrogen Receptor Ligand-Binding Domain Expresses in Escherichia coli." <i>Molecular Endocrinology</i> 6:647-658.	
108	SELMi AND SAMUELS (1991) "Thyroid Hormone Receptor/ and v-erbA." <i>J. Biol. Chem</i> 266:11589-11593.	
109	SHIBATA ET AL. (1997) "Role of Co-activators and Co-repressors in the Mechanism of Steroid/Thyroid Receptor Action." <i>Recent Progress in Hormone Research</i> 52:141-164.	
110	STEPHEN ET AL. (1992) "Reduction of Cardiovascular and Thyroxine-Suppressing Activities of L-t3 by Liver Targeting with Cholic Acid." <i>Biochem. Pharmacol.</i> 13:1969-1974.	
111	SWAFFIELD ET AL. (1995) "A Highly Conserved ATPase Protein as a Mediator Between Acidic Activation Domains and the TATA-Binding Protein." <i>Nature</i> 274:88-91.	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A-B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(use as many sheets as necessary)</i>	Complete if Known	
	Application Number	10/827,121
	Filing Date	April 16, 2004
	First Named Inventor	John D. Baxter
	Group Art Unit	1631
	Examiner Name	Carolyn L. Smith
	Attorney Docket Number	407J-981114US
	Date Submitted	January 7, 2005

112	TAGAMI ET AL. (1997) "Nuclear Receptor Corepressors Activate Rather than Suppress Basal Transcription of Genes that are Negatively Regulated by Thyroid Hormone." <i>Mol. Cell Biol.</i> 17(5): 2642-2648.	
113	TONEY ET AL. (1993) "Conformational Changes in Chicken Thyroid Hormone Receptors α 1 Induced by Binding to Ligand or to DNA." <i>Biochemistry</i> 32:2-6.	
114	TSAI AND O'MALLEY (1994) "Molecular Mechanism of Action of Steroid/Thyroid Receptors Superfamily Members." <i>Ann Rev. Biochem.</i> 63:451-486.	
115	WAGNER ET AL. (1965) "A Structural Role for Hormone in the Thyroid Hormone Receptor." <i>Nature</i> 378(6558): 670-697.	
116	WESTERFIELD ET AL. (1965) "New Assay Procedures for Thyroxine Analogs." <i>Endocrinology</i> 77:802.	
117	YOKOYAMA ET AL. (1995) "Synthesis and Structure-Activity Relationship of Oxamic Acid and Acetic Acid Derivatives Related to L-Thyronine." <i>J. Med. Chem.</i> 38:695-707.	
118	ZENKIE ET AL. (1990) "v-erbA Oncogene Activation Entails the Loss of Hormone-Dependent Regulator Activity of c-erbA." <i>Cell</i> 61:1035-1049.	
119	ZHU ET AL. (1997) "The Differential Hormone-dependent Transcriptional Activation of Thyroid Hormone Receptor Isoforms is Mediated by Interplay of their Domains." <i>J. Biol. Chem.</i> 272(14): 9048-9054.	

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A-B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)	Complete if Known	
	Application Number	10/827,121
	Filing Date	April 16, 2004
	First Named Inventor	John D. Baxter
	Group Art Unit	1631
	Examiner Name	Carolyn L. Smith
	Attorney Docket Number	407J-981114US
	Date Submitted	January 7, 2005

U.S. PATENT DOCUMENTS						
Examiner Initials	Cite No.	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, lines, Where Relevant Passages or Relevant Figures Appeal
		Number	Kind Code (if known)			
	AA	5,298,429		Evans et al.	03-29-1994	
	AB	5,307,287		Cramer III et al.	04-26-1994	
	AC	5,459,077		Moore et al.	10-17-1995	

FOREIGN PATENT DOCUMENTS								
Examiner Initials	Cite No.	Foreign Patent Document			Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T
		Office	Number	Kind Code (if known)				

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS				
Examiner Initials	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.		T
	AD	BOURGUET ET AL. (1995) "Purification, functional characterization and crystallization of the ligand binding domain of the retinoid X receptor." <i>Protein Expression and Purification</i> 6: 604-608.		
	AE	CARPRIK AND GARIÉPY (1993) "The Escherichia coli heat-stable enterotoxin is a long-lived superagonist of guanylin." <i>Infection and Immunity</i> 61(11): 4710-4715.		
	AF	CHATURVEDI ET AL. (1985) "Synthesis and biological evaluation of the superagonist [N alpha-chlorotriazinlaminiflourescein-Ser1, Nle4, D-Phe7]-alpha-MSH." <i>Journal of Pharmaceutical Sciences</i> 74(3):237-240.		
	AG	JORGENSEN ET AL. (1974) "Thyroxine Analogs. 22. Thyromimetic Activity of Halogen-Free Derivatives of 3, 5-Dimethyl-L-thyronine." <i>Journal of Medical Chemistry</i> 17(4): 434-439.		
	AH	LOHIYA ET AL. (1991) " Experience with a potent LH-RH agonist, buserelin, alone and in combination with testosterone for antispermatogetic activity, reversibility and toxicity in langur monkey." <i>Contraception</i> 43(2):187-200.		
	AI	NESTOR ET AL. (1982) "Synthesis and biological activity of some very hydrophobic superagonist analogues of luteinizing hormone-releasing hormone." <i>Journal of Medicinal Chemistry</i> 25(7):795-801.		
	AJ	PUDDICOMBE ET AL. (1996) "The Interaction of an epidermal growth factor/transforming growth factor alpha tail chimers with the human epidermal growth factor receptor reveals unexpected complexities." <i>Journal of Biological Chemistry</i> 271(48): 30392-30394.		
	AK	ROBINSON ET AL. (1995) "Mass Septrometric and biological characterization of guinea-pig corticotropin." <i>Regulatory Peptides</i> 56:89-97.		
	AL	SAGGIO ET AL. (1997) "Adenvirus-mediated gene transfer of a human IL-6 antagonist," <i>Gene Therapy</i> 4:839-845.		
	AM	SAWYER ET AL. (1982) "[half-Cys4, half-Cys10]-alpha-melanocyte-stimulating hormone: a cyclic alpha-melanotrophic exhibiting superagonist biological activity." <i>Proceedings of the National Academy of Science USA</i> 79:1751-1755.		

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.